Long-time leaders in assay innovation, Svar Life Science celebrates the 20th anniversary of their Wieslab® Complement System Assay kits in 2025, underscoring their ongoing commitment to advancing pharma with cutting-edge assay solutions and CRO services.
KEY DRIVER IN BIOPHARMA, immunology is positioning Svar uniquely to support the shift toward immunedriven therapies for complex, chronic, and rare diseases, as well as oncology. Building on its legacy in complement system assessment, Svar has evolved from a trusted immune and cell-based assays provider to a strategic partner in emerging therapeutic modalities.
Since 1992, Svar Life Science has advanced assay technology for the global community, introducing pioneering products such as the Anti-CCP2 assay for rheumatoid arthritis and the iLite® cell-based reporter gene platform. Its Complement Wieslab® kits have become global industry standards, supporting both clinical diagnostics and therapeutic breakthroughs.